Emerging retatrutide, a twin -action drug targeting equally GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Initial clinical studies have demonstrated substantial decreases in overall mass and gains in metabolic markers for people with overweight. Expe… Read More